Exatecan derivatives, linker-payloads, and conjugates and thereof
The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.
1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound has the structure of formula (i):
wherein,
a is 0;
the carbon atoms marked with p1* and p2* each is asymmetric center, and the asymmetric center is S configured, R configured or racemic;
L 1 is selected from —CH 2 — and
R 1 is Cl; and
R 2 is F.
2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the carbon atom marked with p1* is S configured or racemic; and/or the carbon atom marked with p2* is S configured or racemic.
3. The compound of claim 1 , which is selected from:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the carbon atom marked with p1* is S configured; and/or the carbon atom marked with p2* is S configured.
5. The compound of claim 1 , which is selected from:
6. A compound, wherein the compound is:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6 , wherein the compound is: